Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

57.53 +0.70 (+1.23%)
Streaming Delayed Price Updated: 10:59 AM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
News headline image
Thinking About Investing in GLP-1 Stocks? Here Are 3 Things You Need to Know ↗
The GLP-1 market is a massive opportunity in healthcare, and many companies are vying for a piece of it. 
Via The Motley Fool
News headline image
Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse
Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)
From Genentech
Via Business Wire
News headline image
Harvard’s PopEVE AI Cracks the Code of Rare Diseases: Ending the ‘Diagnostic Odyssey’ for Millions
In a landmark achievement for computational biology, researchers from Harvard Medical School and the Centre for Genomic Regulation (CRG) have unveiled PopEVE, a groundbreaking artificial intelligence... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
AI’s ‘Penicillin Moment’: How Generative Models Are Slashing Decades of Antibiotic Research into Months
In a breakthrough that many are calling the "Penicillin Moment" of the 21st century, researchers at the Massachusetts Institute of Technology, led by bioengineering pioneer James Collins, have... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage
Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter and full-year 2025 financial results on February 6, 2026, signaling a definitive shift from a legacy company plagued by patent cliffs to a leaner,... 
Via MarketMinute
Topics Intellectual Property
News headline image
The Phoenix of Big Pharma: A 2026 Deep-Dive into AstraZeneca’s Global Dominance
As of February 6, 2026, AstraZeneca PLC (NASDAQ: AZN) stands as a case study in corporate resilience and strategic reinvention. Once a company teetering on the edge of a massive patent cliff a decade... 
Via Finterra
Topics Economy Government Intellectual Property
News headline image
Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a... 
Via Finterra
Topics ETFs Economy Initial Public Offering
News headline image
These 2 Companies Could Soon Join the Weight Loss Market: Are They Buys? ↗
Wegovy might be getting more competition soon. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Lilly Bolsters Immunology Arsenal with $1.2 Billion Acquisition of Ventyx Biosciences
In a strategic move to solidify its dominance in the burgeoning field of oral anti-inflammatories, Eli Lilly and Company (NYSE:LLY) announced on January 7, 2026, a definitive agreement to acquire... 
Via MarketMinute
News headline image
Eli Lilly Reinforces Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences
In a decisive move to solidify its leadership in the next generation of chronic inflammation and cardiometabolic treatments, Eli Lilly and Company (NYSE: LLY) announced the acquisition of Ventyx... 
Via MarketMinute
News headline image
Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity
From Genentech
Via Business Wire
News headline image
The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape
As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
2 Under-the-Radar Biotech Stocks Set to Boom in 2026 ↗
Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps. 
Via The Motley Fool
Topics ETFs Intellectual Property World Trade
News headline image
The Trillion-Dollar Heavyweight: Eli Lilly Surge Signals Unrivaled Dominance in the GLP-1 Era
Eli Lilly (NYSE: LLY) has once again demonstrated its resilience and market-leading strength, logging a significant 5.2% gain over the last five trading days as of January 22, 2026. This recent rally... 
Via MarketMinute
Topics Economy
News headline image
Abbott Laboratories Shares Plunge 10% Following Q4 Revenue Miss and Diagnostics Weakness
Abbott Laboratories (NYSE: ABT) saw its stock price tumble by nearly 10% in early trading on January 22, 2026, following the release of its fourth-quarter 2025 financial results. Despite meeting... 
Via MarketMinute
Topics Economy
News headline image
Abbott Shares Slump as Revenue Miss and Exact Sciences Acquisition Jitters Overshadow Earnings Beat
Abbott Laboratories (NYSE: ABT) saw its shares retreat by 5.8% in early trading on Thursday, January 22, 2026, following the release of its fourth-quarter financial results. Despite delivering an... 
Via MarketMinute
Topics Earnings Economy
News headline image
Genentech More than Doubles Investment in Holly Springs, North Carolina Manufacturing Facility
From Genentech
Via Business Wire
News headline image
The Trillion-Dollar Pharmacopeia: Eli Lilly’s (LLY) Dominance in the Age of Incretins
As of January 19, 2026, the pharmaceutical landscape is being redefined by a single name: Eli Lilly and Company (NYSE: LLY). Once a steady, century-old stalwart known for its dominance in the insulin... 
Via Finterra
Topics Economy
News headline image
Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance
Date: January 13, 2026 Introduction Amgen Inc. (NASDAQ: AMGN) finds itself at a historic crossroads. Long regarded as the "blue-chip" anchor of the biotechnology sector, the Thousand Oaks-based giant... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
Cashing In at the Peak: Olema Pharmaceuticals Insiders Sell $8 Million in Stock After 300% Surge
Olema Pharmaceuticals (NASDAQ:OLMA) has become the latest focal point of biotech volatility and executive opportunism. Following a staggering 300% surge in its share price over the past year—fueled by... 
Via MarketMinute
News headline image
MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation
MoonLake Immunotherapeutics (NASDAQ: MLTX) shares have experienced a dramatic resurgence this week, climbing over 40% following a pivotal regulatory update that has effectively cleared the path for its... 
Via MarketMinute
Topics Intellectual Property
J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗
Via Stocktwits
Topics Government
News headline image
The Trillion-Dollar Treatment: Eli Lilly Solidifies Dominance as Obesity Drug Boom Enters New Era
As the calendar turns to early 2026, the global pharmaceutical landscape is being redefined by a single, seismic force: the metabolic health revolution. At the epicenter of this transformation stands... 
Via MarketMinute
Topics Economy
News headline image
The Trillion-Dollar Pivot: Eli Lilly Unleashes Volume-Led Strategy to Cement Obesity Market Dominance in 2026
As of January 6, 2026, the landscape of the pharmaceutical industry has been fundamentally reshaped by Eli Lilly and Company (NYSE:LLY), which recently became the first healthcare entity to surpass a... 
Via MarketMinute
Topics Economy
News headline image
Harvard’s CHIEF AI: The ‘Swiss Army Knife’ of Pathology Achieving 98% Accuracy in Cancer Diagnosis
In a landmark achievement for computational medicine, researchers at Harvard Medical School have developed a "generalist" artificial intelligence model that is fundamentally reshaping the landscape of... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
The New Standard in Oncology: Harvard’s CHIEF AI Achieves Unprecedented Accuracy in Cancer Diagnosis and Prognosis
In a landmark advancement for digital pathology, researchers at Harvard Medical School have unveiled the Clinical Histopathology Imaging Evaluation Foundation (CHIEF) model, a "generalist" artificial... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500
As the calendar turns to 2026, Alnylam Pharmaceuticals (Nasdaq: ALNY) stands at the threshold of a new era. Once a speculative pioneer in the arcane world of RNA interference (RNAi), the... 
Via PredictStreet
Topics Economy Intellectual Property Stocks
News headline image
The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature
As of today, January 1, 2026, Abbott Laboratories (NYSE: ABT) stands as one of the most resilient and strategically diversified giants in the global healthcare landscape. While the broader market has... 
Via PredictStreet
Topics Economy Lawsuit World Trade
News headline image
The Year-End Biotech Chill: Adaptive Biotechnologies Braces for J.P. Morgan Crucible Amid Market Sell-Off
As the final trading days of 2025 wind down, the biotechnology sector finds itself caught in a paradoxical "bifurcated" squeeze. While the broader indices have touched record highs this year, a sharp... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.